New HIV prevention drug offers hope, but limited supply hampers access
Health
Business
November 6, 2026
Share this article
Click to view full size
A new HIV-prevention drug that offers nearly complete protection with just two injections a year is raising hopes of curbing the global epidemic, but limited supplies are restricting access in many countries.
The drug, lenacapavir, developed by American pharmaceutical company Gilead Sciences, is a long-acting form of pre-exposure prophylaxis, or PrEP, which helps prevent HIV infection.
The twice-yearly injections could provide an alternative to daily prevention pills and other existing treatments that require more frequent doses.
Health
Business
Need the bigger picture?
Share this article
Comments (0)
Download our mobile app
The portable companion to gazettE. Get notifications, track read articles, and more. The latest news from Trinidad and Tobago, in one place.
